Pinebridge Investments L.P. Raises Holdings in Repligen Co. (NASDAQ:RGEN)

Pinebridge Investments L.P. boosted its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 42.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,110 shares of the biotechnology company's stock after purchasing an additional 5,417 shares during the period. Pinebridge Investments L.P.'s holdings in Repligen were worth $2,607,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGEN. Ballentine Partners LLC boosted its stake in shares of Repligen by 4.0% in the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock valued at $270,000 after buying an additional 72 shares during the period. CIBC Asset Management Inc raised its position in Repligen by 5.0% during the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after purchasing an additional 81 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 90 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in shares of Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock worth $2,087,000 after buying an additional 100 shares in the last quarter. Finally, Peapack Gladstone Financial Corp lifted its position in shares of Repligen by 5.2% during the 4th quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock worth $301,000 after buying an additional 103 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax purchased 250 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.20% of the company's stock.

Repligen Stock Down 1.0 %

RGEN stock traded down $1.44 during trading on Wednesday, reaching $137.99. 975,539 shares of the stock were exchanged, compared to its average volume of 719,992. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The firm's 50 day moving average is $139.19 and its 200 day moving average is $145.93. The firm has a market cap of $7.75 billion, a P/E ratio of -270.57, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the firm earned $0.28 earnings per share. As a group, research analysts forecast that Repligen Co. will post 1.72 EPS for the current year.

Wall Street Analyst Weigh In

RGEN has been the subject of several research reports. Canaccord Genuity Group dropped their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They issued a "buy" rating and a $200.00 target price for the company. JPMorgan Chase & Co. cut their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research note on Tuesday. Evercore ISI started coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. Finally, Royal Bank of Canada decreased their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Repligen currently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.